Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eleven brokerages that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $36.70.

A number of research firms have issued reports on VRDN. HC Wainwright reaffirmed a "buy" rating and issued a $34.00 target price on shares of Viridian Therapeutics in a report on Wednesday, April 23rd. Royal Bank of Canada reduced their price objective on Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. The Goldman Sachs Group dropped their target price on shares of Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. JMP Securities dropped their price objective on shares of Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating on the stock in a report on Wednesday, May 7th. Finally, Needham & Company LLC reissued a "buy" rating and set a $36.00 price objective on shares of Viridian Therapeutics in a report on Tuesday.

Hedge Funds Weigh In On Viridian Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. R Squared Ltd bought a new stake in shares of Viridian Therapeutics during the fourth quarter worth $26,000. Amalgamated Bank grew its holdings in Viridian Therapeutics by 49.7% during the 1st quarter. Amalgamated Bank now owns 2,531 shares of the company's stock worth $34,000 after acquiring an additional 840 shares during the last quarter. Foresite Capital Management VI LLC bought a new stake in Viridian Therapeutics during the 4th quarter worth about $38,000. AlphaQuest LLC increased its position in Viridian Therapeutics by 119.0% in the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock valued at $54,000 after acquiring an additional 1,519 shares in the last quarter. Finally, GAMMA Investing LLC raised its stake in shares of Viridian Therapeutics by 3,892.9% in the first quarter. GAMMA Investing LLC now owns 8,425 shares of the company's stock worth $114,000 after acquiring an additional 8,214 shares during the last quarter.

Viridian Therapeutics Stock Performance

Shares of NASDAQ VRDN traded up $0.01 during trading hours on Friday, hitting $13.67. 568,146 shares of the stock were exchanged, compared to its average volume of 1,191,922. Viridian Therapeutics has a one year low of $9.90 and a one year high of $27.20. The company's 50 day moving average is $13.25 and its 200 day moving average is $16.99. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. The firm has a market capitalization of $1.12 billion, a P/E ratio of -3.17 and a beta of 0.57.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.95) by $0.08. The company had revenue of $0.07 million during the quarter, compared to analysts' expectations of $0.16 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The firm's revenue for the quarter was up .0% compared to the same quarter last year. On average, research analysts expect that Viridian Therapeutics will post -4.03 EPS for the current year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.